Skip to main content

Table 2 Clinicopathologic factors related to CXCR4 expression in 181 HCC patients

From: Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival

   CXCR4 Expression  
Clinicopathologic Parameters No. of Cases Negative (n = 90) Positive (n = 91) P
Age (y)     
   ≤ 60 153 76 (49.7%) 77 (50.3%) 0.975
   > 60 28 14 (50.0%) 14 (50.0%)  
Gender     
   Female 25 16 (64.0%) 9 (36.0%) 0.124
   Male 156 74 (47.4%) 82 (52.6%)  
HBsAg     
   Negative 37 22 (59.5%) 15 (40.5%) 0.184
   Positive 144 68 (47.2%) 76 (52.8%)  
AFP(ng/mL, mean ± SD) 181 4941.25 ± 13475.41 3375.54 ± 11340.86 0.396
   ≤ 20 48 18 (37.5%) 30 (62.5%) 0.017*
   20 – 400 59 26 (44.1%) 33 (55.9%)  
   ≥ 400 74 46 (62.2%) 28 (37.8%)  
Cirrhosis     
   Absence 45 22 (48.9%) 23 (51.1%) 0.897
   Presence 136 68 (50.0%) 68 (50.0%)  
Satellite lesion     
   Absence 127 65 (51.2%) 62 (48.8%) 0.548
   Presence 54 25 (46.3%) 29 (53.7%)  
Tumor size (cm) 181 6.15 ± 3.66 6.75 ± 3.28 0.247
Margins     
   Clear 79 45 (57.0%) 34 (43.0%) 0.087
   Involved 102 45 (44.1%) 57 (55.9%)  
Vascular invasion     
   Absence 95 44 (46.3%) 51 (53.7%) 0.335
   Presence 86 46 (53.5%) 40 (46.5%)  
Portal Vein Thrombosis     
   Absence 153 72 (47.1%) 81 (52.9%) 0.094
   Presence 28 18 (64.3%) 10 (35.7%)  
Hilar Lymph Nodes     
   Absence 170 89 (52.4%) 81 (47.6%) 0.005*
   Presence 11 1 (9.1%) 10 (90.9%)  
UICC T stage     
   T1 91 45 (49.5%) 46 (50.5%) 0.693
   T2 38 17 (44.7%) 21 (55.3%)  
   T3 52 28 (53.8%) 24 (46.2%)  
Edmondson grade     
   Low (I/II) 118 61 (51.7%) 57 (48.3%) 0.468
   High (III/IV) 63 29 (46.0%) 34 (54.0%)  
Bone Metastases     
   Absence 138 81 (58.7%) 57 (41.3%) < 0.001*
   Presence 43 9 (20.9%) 34 (79.1%)  
  1. * Significant P value.